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7RESEARCH Open AccessThe secretome of induced pluripotent stem cells
reduces lung fibrosis in part by hepatocyte
growth factor
Amiq Gazdhar1,2, Iwona Grad3, Luca Tamò1,2,4, Mathias Gugger5, Anis Feki3,6 and Thomas Geiser1,2*Abstract
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrotic lung disease, resulting in
respiratory insufficiency and reduced survival. Pulmonary fibrosis is a result of repeated alveolar epithelial
microinjuries, followed by abnormal regeneration and repair processes in the lung. Recently, stem cells and their
secretome have been investigated as a novel therapeutic approach in pulmonary fibrosis. We evaluated the
potential of induced pluripotent stem cells (iPSC) conditioned media (iPSC-cm) to regenerate and repair the
alveolar epithelium in vitro and improve bleomycin induced lung injury in vivo.
Methods: IPSC-cm was collected from cultured iPSC derived from human foreskin fibroblasts and its biological
effects on alveolar epithelial wound repair was studied in an alveolar wound healing assay in vitro. Furthermore,
iPSC-cm was intratracheally instilled 7 days after bleomycin induced injury in the rat lungs and histologically and
biochemically assessed 7 days after instillation.
Results: iPSC-cm increased alveolar epithelial wound repair in vitro compared with medium control. Intratracheal
instillation of iPSC-cm in bleomycin-injured lungs reduced the collagen content and improved lung fibrosis in the
rat lung in vivo. Profibrotic TGFbeta1 and α-smooth muscle actin (α-sma) expression were markedly reduced in the
iPSC-cm treated group compared with control. Antifibrotic hepatocyte growth factor (HGF) was detected in
iPSC-cm in biologically relevant levels, and specific inhibition of HGF in iPSC-cm attenuated the antifibrotic effect of
iPSC-cm, indicating a central role of HGF in iPSC-cm.
Conclusion: iPSC-cm increased alveolar epithelial wound repair in vitro and attenuated bleomycin induced fibrosis
in vivo, partially due to the presence of HGF and may represent a promising novel, cell free therapeutic option
against lung injury and fibrosis.Introduction
Idiopathic pulmonary fibrosis (IPF) is characterized by a
chronic progressive scaring in the lung mainly due to
improper alveolar wound healing and failure of the alveo-
lar epithelium to re-epithelialize in response to epithelial
injury [1-3]. Although IPF is a devastating disease of un-
known etiology, there is currently no treatment available
to reverse lung destruction and induce alveolar epithelial
regeneration. Most approaches were developed towards* Correspondence: thomas.geiser@insel.ch
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or antifibrotic agents, but with little success.
Cell-based approaches have been proposed recently as
new possibilities to regenerate various organs [4-7], in-
cluding the fibrotic lung [8,9]. This usually implies admin-
istration of exogenously derived stem cells that support
regeneration and modulate the progress of the disease.
Bone marrow-derived stromal cells have been tested in
many laboratory disease models [10] and also in clinical
trials [11,12]. Although the isolation and expansion of
these cells is well established, there are some concerns
with regards to their efficiency and availability, particularly
in older patients [13]. Another obvious source is embry-
onic stem cells, but the complexity of the derivation tech-
nique and ethical issues have hindered advancement inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pluripotent stem cells (iPSCs) has opened a new avenue
for patient-specific cell-based therapies [14]. Mouse [15]
and human iPSCs have been derived with characteristics
of embryonic stem cells, including pluripotency and ability
to differentiate and contribute to the three germ layers
and thus the potential to differentiate into any cell type
[16]. Recently iPSCs have been successfully used for re-
generation in spinal injury, cerebral vascular injury and
acute lung injury in animal models [17-19], providing evi-
dence that iPSCs could be very promising candidates for
cell-based therapies in a variety of diseases.
In clinical settings, direct use of cells is a complex
process and the fate of administered iPSCs in the human
body is not clear. Also, the effect of pluripotency genes
and the transcriptional memory of the somatic cells that
the reprogrammed cells might carry are still not fully
understood [20]. Cell-free methods carrying a similar
therapeutic potential could therefore offer an obvious
advantage for a clinical translation in the future. One of
these possibilities is the use of cell-conditioned media
obtained from stem cells, since released factors from
stem cells normally induce biological responses similar
to the cells when tested in vitro or in vivo. However, the
characteristics of induced pluripotent stem cell condi-
tioned medium (iPSC-cm), including analysis of the
iPSC-cm secretome, and its potential benefits have not
yet been identified in detail.
In the present study we show that iPSC-cm may be a
novel and promising source of cell-based yet cell-free
therapy for pulmonary fibrosis, since iPSC-cm induces
alveolar epithelial repair in vitro and reduces lung fibro-
sis in a bleomycin-induced animal model in vivo, at least
in part by a hepatocyte growth factor (HGF)-dependent
mechanism.
Materials and methods
Generation of induced pluripotent stem cells
Ethical approval
In this study iPSCs were generated using commercially
available cell lines of human foreskin fibroblasts. No ma-
terial from patients or healthy individuals was used and
therefore written or verbal consent was not required,
therefore no ethical approval was needed for this study.
Human foreskin fibroblasts (line CRL-2429; American
Type Culture Collection (ATCC), Rockville, MD, USA)
were used to generate iPSCs as described elsewhere
[21,22]. After expansion, 5 × 104 human fibroblasts were
infected with multiplicity of infection of 5 pSin-EF2-
Nanog-Pur. The cells were treated with puromycin for 5
days and then retransduced with three viruses: pSin-EF2-
Sox2-Pur, pSin-EF2-Oct4-Pur and pSin-EF2-Lin28-Pur
(multiplicity of infection 5). iPSCs were maintained on
irradiated human foreskin fibroblasts (CCD1; ATCC) inknockout Dulbecco’s modified Eagle’s medium supple-
mented with 20% serum replacement, 2 mmol/l Glutamax,
40 μg/ml gentamycin and 100 μmol/l β-mercaptoethanol
(all Gibco, 111 Grand Island, NY, USA) in the presence of
100 ng/ml β-fibroblast growth factor (bFGF; Peprotech
London, UK) and were passaged mechanically every 2 or
3 days.
Embryoid body formation and in vitro differentiation
Cells were differentiated in vitro to examine whether de-
rived iPSCs are able to differentiate into multilineage cell
types. Embryoid bodies were formed after culturing in
suspension in knockout Dulbecco’s modified Eagle’s
medium supplemented with 10% normal calf serum, 1 mM
L-glutamine, 100 μM nonessential amino acids, 100 μM 2-
mercaptoethanol, 50 U/ml penicillin and 50 mg/ml strepto-
mycin (Gibco/Invitrogen) for 7 days, and then transferred
to gelatin-coated dishes. After 14 days, differentiated cells
were examined by immunostaining as described below.
Immunohistochemistry
To confirm pluripotency, the newly generated colonies
were immunostained with OCT3/4 (1:50), NANOG
(1:50), SSEA4 (1:50), and TRA-1-81 (1:200) (Santa Cruz
Biotechnologies, Dallas, Texas, USA) at the given concen-
trations. The colonies were fixed in 3% paraformalde-
hyde for 30 minutes, washed with phosphate-buffered
saline (PBS) and permeabilized with PBS and 0.5% Tri-
ton. After blocking with 5% bovine serum albumin, the
colonies were incubated with primary antibodies at ap-
propriate concentrations overnight, followed by appro-
priate secondary antibody treatment. For multilineage
cell staining, the cells were fixed with 3% paraformal-
dehyde and permeabilized with 0.5% Triton. After
blocking with bovine serum albumin, the cells were in-
cubated overnight with β-tubulin III (ectoderm marker,
1:50), nestin (endoderm marker, 1:50) and alpha smooth
muscle actin (αSMA; mesoderm marker, 1:50) (Santa
Cruz Biotechnologies), followed by appropriate second-
ary antibody treatment. The results were evaluated
using a Leica Fluroscence DMI 4000-B (Leica Microsys-
tems Heerbrugg, St Gallen, Switzerland).
Induced pluripotent stem cell conditioned medium
Ten to 12 iPSC colonies (5.05 ± 0.65 × 105 live cells)
were grown in knockout media without serum replace-
ment and without bFGF on plates coated with Cell Start
(Gibco/Invitrogen) (feeder-free plate) for 24 hours. The
iPSC-cm was collected, centrifuged and further used for
experiments. Knockout media without serum replace-
ment and without bFGF was used as negative control.
Similarly, the conditioned media from CCD1 human
foreskin fibroblasts (ATCC) was used as control condi-
tioned media.
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ratio
Propidium iodide (PI; Invitrogen, Lucerne, Switzerland)
and Annexin V-Alexa647 (BioLegend, Lucerne, Switzerland)
staining was performed to measure cell death and apop-
tosis, respectively. The iPSC colonies growing on Cell Start
coated plates were trypsinized at room temperature for
5 minutes and the cells were suspended in PBS–/– (no cal-
cium, no magnesium; Invitrogen, Grand Island, NY, USA).
The cells were incubated with Annexin V-Alexa647 anti-
bodies (1:50) for 30 minutes. PI was added just before
measurement (1:100). Cells were analyzed by flow
cytometry using an LSRII flow cytometer (BD Biosciences,
Franklin lakes, NJ, USA).
In vitro alveolar epithelial wound repair assay
Human A549 alveolar epithelial-like cells (ATCC) were
cultured to confluence in a 24-well plate using RPMI
1640 containing 10% fetal bovine serum (Gibco). The con-
fluent epithelial monolayer was mechanically wounded
with a pipette tip and further cultured in either iPSC-cm
or control media. Images of the wound surface were cap-
tured at time 0 and after 24 hours using an inverted Leica
DMI4000 B microscope. Quantification of the wound
surfaces was performed using Image J image software
(National institute of health, Bethesda, Maryland, USA),
and alveolar epithelial wound repair was expressed as the
percentage of epithelial wound closure after 24 hours.
Animals
Male Fisher F344 rats (240 to 280 g) were obtained from
Charles River Laboratories GmbH (Sulzfeld, Germany).
Experiments were performed in accordance with the
standards of the European Convention of Animal Care.
The study protocol was approved by the University of
Bern Animal Study Committee.
Instillation of bleomycin
At day 0 of the protocol, F344 rats (220 to 240 g) were
anesthetized by inhalation of 4% isoflurane in a glass
chamber, intubated with a 14 GA intravenous catheter
(Insyte, Madrid, Spain) and instilled intratracheally with
bleomycin (1.28 U/rat) to both lungs. The dosage of
bleomycin was based on preliminary experiments showing
induction of pulmonary fibrosis with lowest mortality.
Instillation of iPSC-cm and control media
Seven days after intratracheal instillation of bleomycin
(1.28 U/rat in both lungs), the animals were anesthetized
as explained above and divided into three groups with
seven in each group. The first group was treated by
intratracheal administration of knockout media alone
500 μl (media control), while in the second group 500 μl
iPSC-cm was intratracheally administered and in thethird group 500 μl conditioned media obtained from fi-
broblasts (CCD1) was instilled as control.Determination of HGF levels and HGF inhibition
experiments
iPSC-cm was collected and HGF levels were measured
using the Bio-Plex suspension array system (Bio-Rad
Laboratories, Basel, Switzerland), according to the manu-
facturer’s instructions.
To study possible mechanisms of iPSC-cm effects on
alveolar epithelial repair in vitro and lung fibrosis in vivo,
we focused on the role of HGF due to its antifibrotic activ-
ities. iPSC-cm was incubated with human HGF neutralizing
antibodies (R&D Systems, Abingdon, UK) for 30 minutes at
37°C. For in vitro experiments, iPSC-cm was incubated
with HGF antibodies at different concentrations (0.01, 0.1,
and 0.8 ng/ml, maximal dose as recommended by the
manufacturer). For in vivo experiments, a dose of 8 μg/ml
HGF antibodies was used.
We instilled iPSC-cm treated with HGF neutralizing
antibodies intratracheally in rats 7 days after bleomycin-
induced lung injury with a volume of 500 μl (n =5). As
controls, we instilled HGF neutralizing antibodies alone
dissolved in the same volume of buffer (n =3). All animals
were sacrificed 7 days after treatment.Assessment
At day 14 (7 days after iPSC-cm instillation) animals were
anesthetized as described above. Thiopental (50 mg/kg
body weight) was administered intraperitoneally. The
heart–lung block was explanted and tissue samples
were collected for further analysis.Histology
Routine hematoxylin and eosin staining was performed
with formalin-fixed tissue sections. To evaluate the extent
of pulmonary fibrosis, the scoring system of Ashcroft and
colleagues [23] was used by a trained pathologist as re-
ported previously [24].Collagen assay
The level of acid-soluble collagen in lung tissue was
determined with a Sircol collagen assay (Biocolor Ltd,
County Antrim, UK) according to the manufacturer’s
instructions. Briefly, the lungs were excised and snap
frozen after having measured the wet weight. The
frozen lungs where homogenized in 1× PBS. The
homogenate was treated with Sircol dye reagent for
30 minutes at room temperature with shaking. After
brief centrifugation, the pellet was dissolved in alkali
reagent and was measured at 540 nm.
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transforming growth factor beta expression levels
Quantitative polymerase chain reaction analysis was car-
ried out to evaluate relative mRNA level changes of trans-
forming growth factor beta 1 (TGFβ1) in different groups.
Total RNA was isolated from the lung using Trizole
(Life Science, Grand Island, NY, USA) following the man-
ufacturer’s instructions. First-strand cDNA was synthe-
sized using the Omniscript RT kit (Qiagen, Duesseldorf,
Germany). The reaction was performed using the Rat
TGFβ1 Taqman gene expression assay (Applied Biosys-
tems, Life Technologies, Grand Island, NY, USA) on 7500
Fast (Applied Bioscience) and the 18s gene was used as a
housekeeping gene (Applied Biosystems, Life Technolo-
gies, Zug, Switzerland). The relative gene expression
changes were calculated using the ΔΔCt method, and
the regulation factor was calculated as RF =2 − ΔΔCt.
Immunohistochemistry for αSMA in paraffin-embedded
lung tissue
The formalin-fixed sections were deparaffinized in a xylene
series and rehydrated through a decreasing ethanol series.
The slides were pretreated by microwave in citrate buffer
(100 mM, pH 7.0) for 10 minutes, washed three times
with 1× Tris-buffered saline +0.1% Tween and incu-
bated overnight at 4°C in αSMA (1:100; Sigma Aldrich, St.
Louis, MO, USA), and stained with EnVision + ™ System–
horseradish peroxidase–3,3′-diaminobenzidine (Dako, Baar,
Switzerland). The positive signals are brown stained by
3,3′-diaminobenzidine.
Results
Generation and characterization of iPSCs
After viral transfection of the human foreskin fibroblast
with vectors carrying the four reprogramming genes,
iPSC colonies were detected after 2 to 3 weeks in cul-
ture. These colonies stained positive for markers of plur-
ipotency, in particular OCT3/4, NANOG, SSEA4 and
TRA-1-81 (Figure 1a).
Embryoid bodies were formed after culturing iPSCs in
suspension for 7 days and subsequent plating for 2 weeks.
Differentiated cells expressing β-tubulin III (ectoderm
marker), nestin (endoderm marker) and αSMA (meso-
derm marker) were detected, indicating that the iPSCs are
pluripotent and can be differentiated into cells of ecto-
derm, endoderm and mesoderm lineages (Figure 1b).
Induced pluripotent stem cells grow well during
preparation of conditioned media (in media without
serum replacement and bFGF)
Annexin–PI staining of the iPSCs growing in serum re-
placement and bFGF-free media revealed no drastic cell
death. The percentage of PI-positive and Annexin-positive
events was 28.2% for PI and 24.9% for Annexin in cellsgrowing in media without serum replacement and bFGF
compared with 27.2% for PI and 25.1% Annexin in cells
growing in normal media (Additional file 1).
Induced pluripotent stem cell conditioned medium
increases alveolar epithelial wound repair in vitro
Wounded monolayers of A549 alveolar epithelial cells
treated with iPSC-cm showed markedly improved alveo-
lar epithelial wound repair in vitro (80.61 ± 8.74% epithe-
lial wound healing after 24 hours as compared with
wounded A549 cells treated with fibroblast conditioned
medium (CCD1-cm; 30.10 ± 2.96%) and serum-free con-
trol medium (12.39 ± 2.21%, P <0.001)), indicating that
iPSC-cm contains biologically active mediators that in-
duce alveolar epithelial repair in vitro to a significantly
higher degree than CCD1-cm or serum-free medium
control (Figure 2).
Induced pluripotent stem cell conditioned medium
reduces fibrosis in bleomycin-injured rat lungs in vivo
Administration of iPSC-cm to bleomycin-injured rat lungs
showed marked improvement of fibrosis as assessed by
histology (Figure 3c) compared with CCD1-cm (Figure 3b)
or serum-free media control (Figure 3a). Semi-quantitative
analysis was performed using the Ashcroft score (1.40 ±
0.24 (iPSC-cm) vs. 3.47 ± 0.16 (CCD1-cm) and 3.4 ± 0.46
(control media), P <0.001) (Figure 3d). In accordance, a
marked reduction in the soluble collagen content was de-
tected in the lungs of iPSC-cm-treated animals compared
with animals treated with CCD1-cm or serum-free media
control (60.46 ± 15.39 μg/mg vs. 176.4 ± 49.86 μg/mg
(CCD1-cm) and 125.8 ± 5.4 μg/mg wet lung (media con-
trol), P <0.001) (Figure 3e), indicating antifibrotic activities
of iPSC-cm in the in vivo bleomycin lung injury model.
HGF secreted by iPSCs markedly contributes to alveolar
epithelial repair in vitro and reduces pulmonary fibrosis
in vivo
Additional experiments were performed to identify soluble
mediators in iPSC-cm that may contribute to the antifi-
brotic effect of iPSC-cm. Based on our previous data on
the antifibrotic effect of HGF [24], we hypothesized that
part of the repair-inducing and antifibrotic activities of
iPSC-cm may be due to HGF secreted by iPSCs. HGF was
present in biologically relevant concentrations in iPSC-cm
(399.23 ± 2.9 ng/ml) and specific inhibition of HGF using
HGF neutralizing antibody resulted in a significant and
concentration-dependent decrease of iPSC-induced alveo-
lar epithelial wound repair in vitro, indicating a central
role for HGF in the epithelial repair-inducing activities of
iPSCs (80.6 ± 8.7% wound closure induced by iPSC-cm vs.
16.4 ± 5.3% closure in presence of 0.1 ng/ml and 3.5 ±
8.4% wound closure in presence of 0.8 ng/ml HGF neu-
tralizing antibody; P <0.001) (Figure 4). These data
Figure 1 Immunophenotypic profiles of induced pluripotent stem cell colonies and differentiation of embryoid bodies. (a) Following
viral transfection of fibroblasts and culture for 2 to 3 weeks in embryonic stem cell culture medium, induced pluripotent stem cell (iPSC) colonies
stained positive for the pluripotent markers OCT4, Nanog, SSEA4 and TRA-1-81 respectively. (b) Derived iPSCs have the ability to differentiate into
the three germ layers in vitro as shown after in vitro differentiation of embryoid bodies: β-tubulin III (ectoderm marker), nestin (endoderm marker)
and smooth muscle actin (SMA; mesoderm marker).
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role in iPSC-cm induced alveolar epithelial repair in vitro.
To evaluate whether the observed antifibrotic effect of
iPSC-cm in vivo is mediated by HGF, HGF neutralizing
antibody was added to iPSC-cm before intratracheal ad-
ministration 7 days after bleomycin lung injury. In the
presence of HGF neutralizing antibody, the antifibrotic
effect of iPSC-cm was abolished (Figure 5a). In accord-
ance, the lung collagen content increased in the pres-
ence of HGF neutralizing antibody (60.5 ± 15.4 μg/mg
after treatment with iPSC-cm vs. 164 ± 9.1 μg/mg wet
lung tissue after treatment of iPSC-cm with anti-HGF
antibody, P <0.001) (Figure 5c) and the Ashcroft score
increased (1.40 ± 0.24 after iPSC-cm vs. 3.95 ± 0.6 after
neutralizing with anti-HGF antibody, P <0.001) (Figure 5d).As controls, HGF neutralizing antibody alone did not show
any antifibrotic effect in our in vivo model (Figure 5b);
moreover, the total collagen content was increased (174.7 ±
1.76 μg/mg wet lung) and the Ashcroft score also worsened
(4.07 ± 0.08, respectively).
Myofibroblasts and TGFβ1 expression are reduced after
treatment with iPSC-cm, in part by a HGF-dependent
mechanism
After treatment with iPSC-cm, cells positive for αSMA
were markedly reduced in the bleomycin-induced lung in-
jury model (Figure 6a) compared with the CCD1-cm-
treated group (Figure 6b) or media control (Figure 6c),
indicating a reduction of myofibroblasts in the injured and
fibrotic areas of the lung. The expression of profibrotic
Figure 2 Induced pluripotent stem cell conditioned medium
improves alveolar epithelial wound repair in vitro. Alveolar
epithelial wound repair in vitro was increased after treatment of the
wounded A549 alveolar epithelial monolayer with induced
pluripotent stem cell conditioned medium (iPSC-cm) compared with
fibroblast (CCD1) conditioned medium (Fibro-cm) and serum-free
media as control. Data indicated as mean ± standard error of the
mean. *P <0.001, **P <0.001,***P <0.0001, respectively.
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pared with control (0.9 ± 0.3 after treatment with iPSC-cm
vs. 3.04 ± 0.4 (media control) and 3.5 ± 0.4 (CCD1-cm),
expressed as relative gene expression changes (2 −ΔΔCt)).
Treatment of bleomycin-injured lungs with iPSC-cm after
addition of neutralizing anti-HGF antibodies resulted inFigure 3 Histological and biochemical analysis of lung fibrosis in vivo
conditioned media. Marked fibrosis was seen in the control groups treated
whereas a significant decrease of fibrosis was observed in (c) the induced
Hematoxylin and eosin staining, scale bar =200 μm. (d) Semiquantitative h
significant reduction of fibrosis after treatment with iPSC-cm compared wit
of the mean (SEM), **P <0.001. (e) In accordance with histological data, the
compared with media control or CCD-1-cm. Data indicated as mean ± SEMan increase of TGFβ1 levels (1.85 ± 0.9, expressed as rela-
tive gene expression changes (2 −ΔΔCt)). In addition, the
extent of myofibroblasts increased as shown with in-
creased αSMA-positive cells after treatment with iPSC-cm
treated with neutralizing anti-HGF antibodies (Figure 6d);
treatment with HGF neutralizing antibody alone did
not reduce αSMA-positive cells (Figure 6e). This data in-
dicate that iPSCs secrete HGF that may be substantially
involved in the antifibrotic effect of iPSC-cm observed
in vivo in the bleomycin-induced lung injury and fibrosis
model.
Discussion
We show in this study that the secretome of iPSCs in-
duces alveolar epithelial repair in vitro and reduces lung
fibrosis in vivo, in part by a HGF-dependent mechanism.
In particular, iPSC-cm showed improved alveolar epithe-
lial wound repair properties in our in vitro lung epithe-
lial wound healing model, and intratracheal instillation
of iPSC-cm attenuates fibrosis in the bleomycin-injured
rat lung, as shown by histology and reduced total collagen
content. Moreover, high levels of HGF were identified in
iPSC-cm, and in the presence of HGF neutralizing anti-
body the effect of iPSCs on alveolar epithelial wound
repair in vitro and reduction of lung fibrosis in the
bleomycin model was in part abolished. This data sup-
port our hypothesis that HGF secreted by iPSCs contrib-
ute to the antifibrotic effect induced by the secretome of
iPSCs.. Histological analysis of injured lungs treated with different types of
with (a) media only (b) or fibroblast conditioned medium (CCD1-cm),
pluripotent stem cell conditioned medium (iPSC-cm)-treated group.
istological analysis of lung fibrosis using the Ashcroft score showed
h media control or CCD-1-cm. Data indicated as mean ± standard error
collagen content was reduced after treatment with iPSC-cm
, *P <0.01, **P <0.001.
Figure 4 Neutralizing anti-hepatocyte growth factor antibodies
inhibit induced pluripotent stem cell-induced alveolar epithelial
repair in vitro. In the presence of neutralizing anti-hepatocyte growth
factor antibodies (HGF Ab), the induction of alveolar epithelial
repair in vitro by induced pluripotent stem cell conditioned medium
(iPSC-cm) was reduced in a dose-dependent manner using the
concentrations of HGF Ab as indicated. Data presented as
mean ± standard error of the mean, **P <0.001.
Figure 5 Neutralizing anti-hepatocyte growth factor antibody inhibit ind
lung fibrosis in vivo. Induced pluripotent stem cell conditioned medium (
neutralizing anti-hepatocyte growth factor antibodies (HGF Ab) added to iP
as assessed by (a) histology, (c) collagen content and (d) Ashcroft score in
HGF Ab there was no reduction in fibrosis, and the Ashcroft score and collage
error of the mean, **P <0.001).
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ized by pulmonary scar formation leading to respiratory
failure and death. The prognosis is extremely poor, the
exact pathophysiology is still unknown and there is so
far no promising treatment available. However, recent
evidence suggests that dysregulated alveolar repair pro-
cesses contribute to the development of fibrosis in the
lung [25]. Failure of the normal wound healing processes
in response to repeated alveolar injuries thus led to an
imbalance of the chemokines, cytokines, growth factors
and enzymes such as proteinases and their inhibitors,
leading to uncontrolled proliferation of fibroblasts, excess
deposition of extracellular matrix and accumulation of
myofibroblasts [26,27]. A well regulated repair process in
response to injury is essential to avoid the development of
fibrosis. In recent times, cell-based therapies have been
tried as a novel therapeutic option for fibrotic diseases,
also in the lung [7,28].
iPSCs have gained lot of attention in recent years due
to their potential for regenerative medicine. Introduction
of four genes to somatic cells leads to generation of
iPSCs, which results in pluripotency comparable with
embryonic stem cells [14,21]. This technique has beenuced pluripotent stem cell conditioned medium-induced reduction of
iPSC-cm)-induced reduction in lung fibrosis was prevented by
SC-cm prior to intratracheal instillation in the bleomycin-injured lung
the lung. (b) When bleomycin-injured animals were treated with only
n content were significantly high. Data presented as mean ± standard
Figure 6 Myofibroblast accumulation in vivo is reduced after treatment with induced pluripotent stem cell conditioned medium, in
part by a hepatocyte growth factor-dependent mechanism. Immunohistochemistry was performed to detect myofibroblasts using alpha
smooth muscle actin (αSMA) antibody. In (c) media control and (b) fibroblast (CCD1) conditioned medium-treated animals, strong αSMA staining
was detected; whereas in (a) induced pluripotent stem cell conditioned medium (iPSC-cm)-treated animals, the number of αSMA-positive signals
was reduced. (d) When iPSC-cm was pretreated with neutralizing anti-hepatocyte growth factor (HGF) antibody before intratracheal instillation to
bleomycin-injured lungs, αSMA positivity increased compared with treatment with iPSC-cm alone. (e) Treatment with HGF neutralizing anti-HGF
alone did not show any effect compared with control animals. Scale bar =500 μm.
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cell types [29,31-34], and has been used for rare genetic
disorders in clinical settings [35,36]. Some studies have
shown beneficial effects of iPSCs in experimental animal
models of various diseases yet the fate of implanted
iPSCs in the diseased body is not yet described; more-
over, there are concerns about malignant transformation
of the iPSCs after application. Recent studies, however,
showed the therapeutic potential of the conditioned
media of stem cells in various disease models [37,38];
the study by Gupta and colleagues showed in an in vitro
co-culture model that mesenchymal stem cells secrete
anti-inflammatory cytokines and decrease the tumor ne-
crosis factor alpha release of macrophages in the acute
lung injury model [39].
We hypothesized that iPSC-cm induces alveolar epi-
thelial repair in an in vitro alveolar wound repair model
and reduces pulmonary fibrosis in a bleomycin-induced
lung injury and fibrosis model in the rat. A paper by
How and colleagues published recently has reported
therapeutic benefit of the iPSC secretome in lung injury
[40]. In the present study, the results obtained with our
in vitro alveolar epithelial wound repair assay and
bleomycin-induced fibrosis model in vivo suggest that
iPSC-cm may contain some biologically relevant se-
creted mediators which enhance alveolar epithelial repair
and regeneration and reduce lung fibrosis in vivo.
HGF is an important growth factor and plays a major
role in lung development in the early embryonic stages
[41], specifically by regulating epithelial development
and efficient branching morphogenesis [42], and also
latter in the adult lung and in various disease processesincluding pulmonary fibrosis [43,44]. Altered pro-HGF
production by fibroblasts from IPF patients has been re-
ported [45]. HGF is known to have beneficial effect
when administered in the bleomycin-induced fibrosis
models [46,47]. In particular, we showed that targeted,
electroporation-mediated expression of HGF specifically
in alveolar type II epithelial cells results in a reduction
of lung fibrosis in the bleomycin-induced lung fibrosis
model [24]. High levels of HGF were detected in the
iPSC-cm, and thus we hypothesized that the antifibrotic
effect observed in the present study both in vitro and
in vivo is partly mediated by HGF. Our hypothesis was
supported by a series of inhibiting experiments where
the alveolar epithelial repair activities of iPSC-cm treated
with HGF neutralizing antibody was markedly dimin-
ished in vitro in a dose-dependent manner. Furthermore,
the iPSC-cm pretreated with anti-HGF neutralizing anti-
body further aggravated the fibrotic process when in-
stilled in the bleomycin-injured rat lungs; the total
collagen content of the lung was increased and also the
histological score showed aggravated fibrosis. These
findings indicate that HGF present in the iPSC-cm re-
duces fibrosis and plays a crucial role in alveolar epithe-
lial repair in vitro and contributes significantly to the
antifibrotic properties of iPSC-cm.
TGFβ1, an important profibrotic mediator, was reduced
in lung tissue homogenate after instillation of iPSC-cm in
the bleomycin-injured rat lungs compared with controls.
Interestingly, when iPSC-cm treated with HGF neutraliz-
ing antibody was instilled, TGFβ1 levels increased drastic-
ally in the lung tissue homogenate. αSMA was markedly
reduced in the interstitial space after iPSC-cm treatment
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stantial reduction of myofibroblasts in the fibrotic lung tis-
sue after iPSC-cm treatment as reported recently [40],
supporting the antifibrotic effect induced by iPSC-cm in
our in vivo model. However, our study differs in many as-
pects. In the study by How and colleagues, iPSC-cm was
administered 24 hours after bleomycin challenge and ana-
lysis was performed at day 3 post treatment [40], which is
an acute model with high inflammatory component. We
performed the iPSC-cm treatment 7 days after bleomycin
administration, and performed analysis 7 days after iPSC-
cm treatment (14 days after bleomycin administration).
We demonstrate the beneficial effect of iPSC-cm in a
more chronic model of bleomycin-injured rat lung, where
the fibrotic component overwhelms the acute inflamma-
tory response to bleomycin.
Interestingly enough, the treatment of iPSC-cm is very
effective in the bleomycin-injured rat lungs, indicating
that the secreted mediators have a strong therapeutic ef-
fect and can be a good substitute for cell therapy. How-
ever, the detailed analysis of the iPSC-cm is required
and also its long-term effect needs to be evaluated. Most
interestingly, iPSCs offer the possibility to generate
patient-tailored therapy when the patient’s own somatic
cells can be reprogrammed to iPSCs and used for treat-
ment, thus circumventing the immune response that is
usually associated with therapies using cells from differ-
ent donors. Using iPSC-cm from patient-specific iPSCs
will therefore offer a more promising, safe and effective
therapeutic option.
In the current study we generated iPSCs using the
pSIN vectors (nonreplicating lentiviral vectors) that are
not expressed in the reprogrammed cells [48], yet the con-
cern of using the viral vector cannot be ignored. New non-
viral methods for generation of iPSCs have been reported
recently using mRNA [49,50] and recombinant protein
[51]; since the iPSC is a new and evolving technology it
will take some time and effort to modify the existing pro-
tocols, but enormous strides have been already made in
the field aiming to reduce the use of xeno products for
iPSC generation and culture [52]. Considering these tech-
nical advances in the future, the conditioned media ob-
tained from iPSCs, generated using nonviral methods and
cultured in xeno-free conditions, might make clinical
application easier. Another concern is the method to
produce large amounts of iPSC-cm; some efforts have
been made in this direction [53], but a compact and effi-
cient bioreactor needs to be engineered to meet the
clinical criteria.
In summary, we show for the first time that iPSC-cm
induces alveolar repair in vitro and reduces bleomycin-
induced lung injury and fibrosis in vivo. Although further
studies need to be performed, we assume that improve-
ment of alveolar epithelial repair induced by iPSC-cmcontributes significantly to the antifibrotic effect we ob-
served after intratracheal iPSC-cm instillation. HGF ob-
viously represents a crucial mediator in the secretome
of iPSCs and contributes to the pro-repair and anti-
fibrotic properties of iPSC. However, more detailed ana-
lysis of the secretome of iPSCs still needs to be elucidated.
Conclusions
In the first proof-of-concept study we show that condi-
tioned media obtained from iPSCs improved alveolar
epithelial repair in vitro and attenuated bleomycin-
induced lung injury and fibrosis in vivo, partially by a
HGF-dependent mechanism. IPSC-cm therefore has
therapeutic potential in lung fibrosis and might offer a
promising novel option for patients suffering from pul-
monary fibrosis, taking advantage of a novel cell-based,
yet cell-free therapy based on the generation of iPSCs.
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